Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Abstract

BACKGROUND Standard first-line antiretroviral therapy for HIV-1 infection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these drugs have limitations. We assessed the 96 week efficacy and safety of an NtRTI-sparing regimen. METHODS Between August, 2010, and September, 2011, we enrolled treatment-naive adults into this… (More)
DOI: 10.1016/S0140-6736(14)61170-3

Topics

8 Figures and Tables

Cite this paper

@article{Raffi2014RitonavirboostedDC, title={Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.}, author={François Raffi and Abdel G. Babiker and Laura Richert and Jean-Michel Molina and Elizabeth C. George and Andrea Antinori and Jos{\'e} Ram{\'o}n Arribas and Jesper Grarup and Fleur Hudson and Christine Schwimmer and Juliette Saillard and C{\'e}drick Wallet and Per O Jansson and Clotilde Allavena and Remko van Leeuwen and J. F. Delfraissy and Stefano Vella and Genevi{\`e}ve Ch{\^e}ne and Anton Louis Pozniak}, journal={Lancet}, year={2014}, volume={384 9958}, pages={1942-51} }